natgillin/translations-raw huggingface dataset:
[Item 4′] A CAP dependent endonuclease inhibitor according to item 1′, wherein is hydrogen, halogen, hydroxy, carboxy, lower alkyl optionally substituted by substituent group A, lower alkenyl optionally substituted by substituent group A, lower alkyloxy optionally substituted by substituent group A, lower alkyl carbonyl optionally substituted by substituent group A, lower alkyloxycarbonyl optionally substituted by substituent group A, heterocyclic group optionally substituted by substituent group A, or 
Spoj, njegova farmaceutski prihvatljiva sol, ili njegov solvat, za uporabu u liječenju i/ili prevenciji infektivne bolesti gripe prema zahtjevu 1, naznačen time, da R' je vodik, halogen, hidroksi, karboksi, niži alkil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkenil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksi prema potrebi supstituiran sa supstituentskom skupinom A, niži alkilkarbonil prema potrebi supstituiran sa supstituentskom skupinom A, niži alkiloksikarbonil prema potrebi supstituiran sa
The body support cushion of claim 16 wherein the outer cover includes phase change material. 
Jastuk za podržavanje tijela u skladu s patentnim zahtjevom 9, naznačen time što vanjski pokrov (44) uključuje materijal promjenjive faze.
The present method offers the advantage it is possible to desorb the polyphenols and/or proteins from the PVPP particles during the separation of the slurry into a yeast-enriched fraction and a PVPP-enriched fraction, by combining the liquid comprising the slurry with a caustic aqueous liquid prior to or during the sedimentation separation to increase the pH of the combined liquids to at least 10.0, preferably to at least 11.0. 
Postupak prema bilo kojem od prethodnih Zahtjeva, gdje se tekućina koja sadrži kašu kombinira s vodenastom baznom tekućinom prije ili tijekom separacije putem sedimentacije kako bi se povećala pH vrijednost kombiniranih tekućina do vrijednosti od najmanje 10,0, a poželjno do vrijednosti od najmanje 11,0.
Use of deglycosylated long pentraxin PTX3 according to claim 1 or 3 or of desialidated long pentraxin according to claim 2 or 3 for the preparation of a medicament for the prevention or treatment of inflammatory diseases, including autoimmune diseases, tumours, diseases due to abnormal activation of growth factor FGF-2, female fertility disorders, tissue infarct and bone or cartilage diseases. 
Primjena deglikoziliranog dugog pentraksina PTX3 prema zahtjevu 1 ili 3 ili desijalidiranog dugog pentraksina prema zahtjevu 2 za dobivanje lijeka za prevenciju ili liječenje upalnih bolesti uključujući autoimune bolesti, tumore, bolesti uslijed abnormalno aktivacije faktora rasta FGF-2, poremećaje plodnosti kod žena, infarkt tkiva i bolesti kostiju ili hrskavice.
reducing the compound of formula VII to the compound of formula VIII 
Cc) redukciju spoja s formulom VII u spoj s formulom VIII u spoj s formulom VII
The adenovirus according to claim 1, wherein said vector comprises more than one capsid protein from SAdV-39, said capsid protein selected from one or more of a penton protein of SAdV-39, amino acids 1 to 532 of SEQ ID NO: 6 and a fiber protein of SAdV-39, amino acids 1 to 489 of SEQ ID NO: 22. 
Adenovirus prema patentnom zahtjevu 1, gdje spomenuti vektor sadrži više od jednog kapsidnog proteina SAdV-39, spomenuti kapsidni protein odabran od jednog ili više penton proteina SAdV-39, amino-kiseline 1 do 532 sa SEQ ID NO: 6 i vlaknasti protein SAdV-39, amino-kiseline 1 do 489 sa SEQ ID NO: 22.
Usually, in a single phase system, an electrical device (i.e. 
Uobičajeno, u jednofaznom sustavu, električni uređaj (tj.
wherein X2 is —O— or —S—, n3 is an integer from 1 to 6 and R2 is as defined above; wherein: 
Re gdje X> jest ili -S-, n' je cijeli broj od 1 do 6, a R? je kao što je gore definiran,
wherein a transmission delivery system descriptor including the identifier of the PLP, the identifier of the transmission system, and a guard interval field in a TS loop of the NIT maps transport streams to PLPs in data slices of the transmission systems. 
HR P20120617 T1 gdje deskriptor dostavnog sustava prijenosa uključujući identifikator PLP-a, identifikator sustava prijenosa i zaštitna intervalna polja u TS petlji NIT mapa prenose tokove do PLP-ova u podatkovnim komadima sustava prijenosa. 14.
The solution according to claim 1, further comprising at least one preservative agent. 
Otopina prema zahtjevu 1, naznačena time da nadalje sadrži barem jedno sredstvo za konzerviranje.
A process according to claim 9, wherein the composition has an operating characteristic of superheat during refrigeration in the range of: 
Postupak prema bilo kojem prethodnom zahtjevu, naznačen time da rashladna tvar ima radnu karakteristiku pregrijavanja tijekom hlađenja u rasponu od:
Mean Number of sites 
Broj međunarodne prijave:
The central cylinder 62 is open at both sides for slidable receipt of an adjacent portion of the ball spline nuts 42, 43 disposed one on each side of the central cylinder 62. 
Središnji cilindar (62) je otvoren na obje strane kako bi u njega klizanjem mogle ući bilo koja od kuglasto-klinastih matica (42), (43) koje se nalaze svaka s jedne strane središnjeg cilindra (62).
and R5, taken together with the intervening oxygen and boron atoms, form an optionally substituted 5-membered ring. 
(d) R'i R', uzeti zajedno sa atomima kisika i bora koji se nalaze između, formiraju izborno supstituirani 5-člani prsten.
It is obvious that these temperatures, namely both the normal temperature and the filling temperature, are strongly dependent on the filling medium. 
Očigledno je da su te temperature, naime obje, normalna temperatura i temperatura punjenja, jako ovisne o punilu.
the carbocyclyl portion of the carbocyclylalkyl and the heterocyclyl portion of the heterocyclylalkyl optionally are substituted with one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, carboxy, hydroxy, alkyloxy, alkenyloxy, alkynyloxy, halo, nitro, cyano, azido, oxo, and amino, and 
karbociklil dio od karbociklilalkila i heterociklil dio od heterociklilalkila po izboru su supstituirani jednim ili više supstituenata neovisno odabranima iz skupine koja sadrži alkil, alkenil, alkinil, karboksi, hidroksi, alkiloksi, alkeniloksi, alkiniloksi, halo, nitro, cijano, azido, okso i amino, i
, 15.8 and 16.5 degrees 2theta ± 0.2 degrees 2theta. The polymorph of 6-(Piperidin-4-yloxy)-2H-isoquinolin-1-one hydrochloride as claimed in claim 2, which is polymorph 2 and has at least reflection in an X-ray powder diffractogram using CuKa1 radiation at 
Polimorf 6-(piperidin-4-iloksi)-2H-izokinolin-1-on hidroklorida prema zahtjevu 2, naznačen time da je polimorf 2 i ima refleksiju u difraktogramu X-zraka na prahu korištenjem CuKa1 zračenja barem kod 8.1, 15.8, 16.5, 22.2, 25,0 i 26.6 stupnjeva 2theta ± 0.2 stupnjeva 2theta.
amino acids having a sequence at least 80% identical to a light chain variable domain sequence selected from L1-L27; 
aminokiseline koje imaju slijed najmanje 80% identičan slijedu SEQ ID NO:363; di.
The solvent was removed in vacuo. 
Otapalo je uklonjeno in vacuo.
A compound according to Claim 1, a salt thereof or a hydrate of the foregoing, wherein R1 represents a group represented by the formula -N(CH3)R11i, wherein R11i represents n-propyl, n-butyl, pyrrolidin-3-yl or piperidin-4-yl, and R11i may be substituted with a substituent selected from Substituent Group H, wherein Substituent Group H consists of dimethylamino, diethylamino, dimethylaminoethyl, dimethylaminopropyl and 1-methylazetidin-3-yl. 
Spoj prema zahtjevu 1, njegova sol ili hidrat navedenog, naznačen time da R' predstavlja skupinu prikazanu sa formulom -N(CH;)R''i, pri čemu R''' predstavlja n-propil, n-butil, pirolidin-3-il ili piperidin-4-il, i R'"' može biti supstituiran sa supstituentom odabranim iz supstitucijske skupine H, pri čemu supstitucijska skupina H sadrži dimetilamino, dietilamino, dimetilaminoctil, dimetilaminopropil i 1-metilazetidin-3-il.
calcium chloride. 
(11) kalcijevom kloridu.
Use of Modulators to Affect Peptides of the Disclosure 
Broj objave europskog patenta:
Animals are then administered the test compound as an oral or i.v. 
Na životinjama je zatim primijenjen ispitivani spoj, bilo oralnim ili 1.v.
a monoclonal antibody comprising a light chain variable domain containing residues 44-54, 70-76 and 109-117 of SEQ ID NO:2 or SEQ ID NO:6; 
(i) monoklonalnog antitijela koje sadrži varijabilno područje lakog lanca koje sadrži ostatke 44-54, 70-76 i 109-1170d SEQ ID br. 2;
Ultrasound is defined herein as energy at a frequency in the range of 10 kHz to 10 MHz. 
Ultrazvuk je ovdje definiran kao energija pri frekvenciji u rasponu od 10 kHz do 10 MHz.
The drum type conveyor is provided with said guide 241 to restrict the item 10 to its location in the cavity 222 while the drum is being rotated from the second position with the space 222 facing the input receiving area 210 to the third angular position where the opening of the cavity 222 is facing the first output 224 . 
Prema gore orijentirano skladište prema patentnom zahtjevu 13 ili 14, naznačeno time, što transportno sredstvo dalje sadrži sredstvo (241) za vođenje prilagođeno da zadrži povratni predmet koji se nalazi u udubljenju dok je bubanj postavljen u rotacijski položaj između drugog rotacijskog položaja i prvog izlaza ili drugog izlaza.
This technique requires highly sophisticated hot-melt granulation for producing fine particles, and may have adverse effects on heat sensitive molecules or restrict drug release adversely. U.S. Pat. No. 4,865,851 describes cefuroxime axetil in particulate form coated with an integral coating of lipid or a mixture of lipids. 
Ta tehnika zahtijeva visoko sofisticiranu granulaciju uz taljenje toplinom za dobivanje finih čestica te može imati obrnute učinke na molekule osjetljive na toplinu ili nepovoljno ograničavajuće djelovanje na oslobađanje lijeka, U.S. Patent No. 4,865,851 opisuje cefuroksim aksetil u obliku čestica obloženih cjelovitom oblogom lipida ili mješavine lipida.
U is an O-activating group; 
U je skupina koja aktivira O;
R2A is selected from the group consisting of an unsubstituted C1-6 alkyl, a halogen substituted C1-6 alkyl, a hydroxy substituted C1-6 alkyl, an alkoxy substituted C1-6 alkyl, a sulfenyl substituted C1-6 alkyl, an optionally substituted C2-6 alkenyl, an optionally substituted C2-6 alkynyl, an optionally substituted C3-6 cycloalkyl, an optionally substituted -O-C1-6 alkyl, an optionally substituted -O-C3-6 alkenyl, an optionally substituted -O-C3-6 alkynyl and cyano; 
RA je odabran iz skupine koja sadrži nesupstituirani C,galkil, halogen supstituirani Cig alkil, hidroksi supstituirani C, galkil, alkoksi supstituirani C1.4 alkil, sulfenil supstituirani Cisalkil, po izboru supstituiran C2.4 alkenil, po izboru supstituiran C24 alkinil, po izboru supstituiran C3g cikloalkil, po izboru supstituiran -O-C1.4 alkil, po izboru supstituiran -O-C34 alkenil, po izboru supstituiran -O-C34 alkimil i cijano;
A compound according to claim 1 of the formula: 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je spoj formule: 10
After filtering the solvent was eliminated at reduced pressure. 
Nakon filtracije otapalo se odstrani pod smanjenim tlakom.
The variant of claim 26, wherein said insertion is A3AY. 
Varijanta iz zahtjeva 26, naznačena time, da navedeni umetak je A3AY, .
a phenyl group, a naphthyl group or an isoquinolinyl group, each of which may be substituted with 1 to 3 substituents selected from the group B [wherein the group B consists of a halogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group, an amino group which may be substituted with one or two C1-C6 alkyl groups, a morpholino group, a piperazino group which may be substituted with a C1-C6 alkyl group(s), a C1-C6 alkanoylamino group, and a C1-C6 alkylsulfonylamino group], 
(dil) fenilnu skupinu, naftil skupinu ili izokinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 3 supstituenta odabrana iz skupine B [pri čemu skupina B sadrži atom halogena, C;-Cg alkilnu skupinu, C;- CÂ« alkoksi skupinu, amino skupinu koja može biti supstituirana sa jednom ili dvije Ci-Cg alkilne skupine, morfolino skupinu, piperazino skupinu koja može biti supstituirana sa C;-Cg alkil skupinom(ama), C,-C4 alkanoilamino skupinu, te C;-Cg alkilsulfonilamino skupinu], R* predstavlja atom vodika ili C,-Cg alkilnu skupinu, i
The compound of claim 1, wherein X is CH2. 
Spoj prema zahtjevu 1, pri čemu X je N.
The compound of claim 3, wherein X is Cl. 
Spoj prema Zahtjevu 3, pri čemu X predstavlja C1.
For example known polymers generate smoke as they are heated by the laser beam, which may contaminate the contents of the vial. 
Na primjer, poznati polimeri stvaraju dim kada se zagriju laserskim snopom, koji dim može kontaminirati sadržaj bočice.
When smoked under FTC conditions, the article delivered 8 mg of WTPM over the initial three puffs; 7 mg WTPM over puffs 4-6; and 5 mg WTPM over puffs 7-9. 
Kada se puši pod FTC uvjetima, proizvod je isporučio 8 mg MUČM tijekom početna tri dima; 7 mg MUČM tijekom dimova 4-6; i 5 mg MUČM tijekom dimova 7-9.
The solvent was evaporated and purification by chromatography on silica gel eluting with a mixture of dichloromethane/methanol in the proportions 100/0 to 70/30 led to compound in the form of a yellow solid (0.328 g). 
Otapalo se otpari, a pročišćavanje kromatografijom na silikagelu, uz eluiranje smjesom diklormetan/metanol, u odnosima od 100/0 do 70/30, daje spoj u obliku žute krutine (0,328 g).
The PLG low-burst copolymer material of claim 1 wherein the removed copolymer fraction is about 2% to about 20% by weight of the sum of the weights of the removed copolymer fraction and the PLG low-burst copolymer material. 
PLG kopolimerni materijal sa smanjenim efektom naglog oslobađanja iz patentnog zahtjeva 1, gdje uklonjena kopolimerna frakcija je oko 2% do oko 20% po masi od zbira masa uklonjene kopolimerne frakcije i PLG kopolimernog materijala sa smanjenim efektom naglog oslobađanja.
WO2012046145 WO2004080474 A topical composition comprising an extract from Coriolus versicolor, for use in the prevention and/or treatment by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent selected from the group consisting of human papiloma virus (HPV), Gardnerella vaginalis, Mobiluncus, Bacteroides, Mycoplasma, Trichomonas vaginalis, Staphylococcus epidermis, Streptococus alpha and S. epidermidis. 
Pripravak za lokalnu primjenu, naznačen time što sadrži ekstrakt Coriolus versicolor, za uporabu u prevenciji i/ili liječenju, vaginalnom ili cervikalnom primjenom lijeka, vaginalnog ili cervikalnog poremećaja uzrokovanog infektivnim agensom odabranim iz skupine koju čine humani papiloma virus (HPV), Gardnerella vaginalis, Mobiluncus, Bacteroides, Mycoplasma, Trichomonas vaginalis, Staphylococcus epidermis, Streptococus alpha 1 S. epidermidis.
The agent for the treatment of spinal canal stenosis according to claim 5, wherein the spinal canal stenosis is cervical spinal canal stenosis, thoracic spinal canal stenosis, lumbar spinal canal stenosis, diffuse spinal canal stenosis or sacral stenosis. 
Sredstvo u skladu s patentnim zahtjevom 1, namijenjeno upotrebi u skladu s patentnim zahtjevom 1, naznačeno time što je stenoza kralježničnog kanala stenoza kanala cervikalne kralježnice, stenoza kanala torakalne kralježnice, stenoza kanala lumbalne kralježnice, difuzna stenoza kralježničnog kanala 1li stenoza kanala sakralne kralježnice.
from 0.05 to 5% by weight of at least one superfluidizing agent; characterised in that the composition comprises: 
(d) od 0,05 do 5 % po masi barem jednog sredstva za superfluidiziranje; naznačen time što sastav sadrži:
A single chain protein multimer according to any one of claims 1 to 4, further comprising a carrier peptide coupled releasably at the N-terminus thereof, the carrier peptide providing a Met residue at its N-terminus and, at its C-terminus, a site cleavable by said enzyme. 
Jednolančani proteinski multimer prema bilo kojem od zahtjeva 1 do 4, koji dalje obuhvaća protein nosač spojen na odvojiv način na njegov N-kraj, protein nosač ima Met ostatak na svom N-kraju, a na svom C-kraju mjesto koje se cijepa enzimom.
The pharmaceutical composition according to claim 4, wherein the pH of the solution is in the range of 7.0 to 8.0. The pharmaceutical composition according to claim 6, wherein the pH of the solution is in the range of 7.2 to 7.8. 
Farmaceutski sastav prema bilo kojem od zahtjeva 7 do 9, naznačen time da je pH vrijednost otopine u rasponu od 7,0 do 8,0, poželjno u rasponu od 7,2 do 7,8, i još poželjnije oko 7,4.
At this stage most patients lose insight and are apparently unaware of their surroundings. 
U tom stadiju većina pacijenata gubi spoznavanje i vjerojatno nisu svjesni svojeg okruženja.
Method according to claim 2, wherein the conversion coating is made by spraying the strip with an aqueous solution of 5 to 50 g/l, preferably 15 to 25 g/l, of a first initial solution comprising < 1 wt.-% diammonium dimolybdate and 5 to 10 wt.-% hexafluorozirconic acid, and 0.01 to 0.3 g/l, preferably 0.1 to 0.3 g/l, of a second initial solution comprising 10 to 25 wt.-% ammonium fluoride and 10 to 25 wt.-% ammonium hydrogen difluoride. 
Postupak prema zahtjevu 2, naznačen time, da se konverzijski sloj izvodi putem sprejanja trake s vodenom otopinom od 5 do 50 g/l, poželjno od 15 do 25 g/l prve početne otopine koja sadrži < 1 masenog % diamonijdimolibdata i od 5 do 10 masenih % heksafluorocirkonijske kiseline, te od 0,01 do 0,3 g/l, poželjno od 0,1 do 0,3 g/1 druge početne otopine koja sadrži od 10 do 25 masenih % amonij-fluorida i od 10 do 25 masenih % amonij- vodikovog difluorida.
The extended release dosage form of any one of claims 3 to 7, wherein the composition comprises at least about 80 % (by wt) polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000. 
Oblik za doziranje s produljenim otpuštanjem prema zahtjevu 11, naznačen time da sastojak sadrži barem oko 80 % (po težini) polietilen oksida koji ima, bazirano na reološkim mjerenjima, približnu molekulsku masu od barem 1,000,00.
The separation apparatus according to claim 1, characterized in that at the conveyor's outlet a scraper is provided for removal of particles of the first fraction that stick to the surface of the conveyor. 
Uređaj (1) za razdvajanje prema zahtjevu 1 ili 2, naznačen time što je na izlazu transportera postavljen strugač (23) za uklanjanje čestica prve frakcije koje se lijepe za površinu transportera (17).
a light chain variable region amino acid sequence encoded by the nucleotide sequence selected from the group consisting of SEQ ID NOS: 136-138 and 142-144; 
Izolirano IL-23p19 antitijelo prema patentnom zahtjevu 1, naznačeno time da sadrži varijabilnu regiju lakog lanca aminokiselinske sekvence kodirane od strane nukleotidne sekvence izabrane od grupe koja se sastoji od SEQ ID NOS:142-144.
A mono-HCl salt of the compound of formula (I), as claimed in claim 3, in crystalline form which has an X-ray powder diffraction pattern with specific peaks at 2-theta = 12.3, 13.9, 9.3, 23.3, 18.7, 16.0, 24.6, 26.8, 28.0° with a measurement error for each diffraction angle being plus or minus 0.2°. 
Mono-HCI so spoja formule (I), prema patentnom zahtjevu 3, u kristalnom obliku koji ima obrazac rentgenske difrakcije praha sa specifičnim pikovima na 2-teta = 12.3, 13.9, 9.3, 23.3, 18.7, 16.0, 24.6, 26.8, 28.0" sa greškom mjerenja za svaki difrakcijski kut koji je plus ili minus 0.2".
wherein said determination is indicative of the test compound being a GLP-1 secretagogue; determining the blood GLP-1 level in a biological sample obtained from a mammal, said mammal having been administered with a compound in the presence of which less of said complex is formed in step (c); 
(d) određivanje nivoa GLP-1 u krvi u biološkom uzorku dobivenom iz sisavca, pri čemu je navedenom sisavcu bio primjenjen spoj u prisutnosti kojeg je formirano manje navedenog kompleksa u koraku (c); pri čemu je sposobnost test spoja da poveća nivo GLP-1 u krvi nadalje indikativna da je test spoj GLP-1 sekretogog.
wherein the term "substituted" denotes substitution by any of the substituents recited in the subsequent claims or by halogen; alkyl; hydroxyl; alkoxy; alkoxyalkyl; amino; alkylamino; carboxy; nitro; cyano; thiol; thioether; imine; imide; amidine; guanidine; enamine; aminocarbonyl; acylamino; phosphonato; phosphine; thiocarbonyl; sulfonyl; sulfone; sulfonamide; ketone; aldehyde; ester; urea; urethane; oxime; hydroxyl amine; alkoxyamine; aralkoxyamine; N-oxide; hydrazine; hydrazide; hydrazone; azide; isocyanate; isothiocyanate; cyanate; thiocyanate; oxygen (=O); B(OH)2, O(alkyl)aminocarbonyl; cycloalkyl, which may be monocyclic or fused or non- fused polycyclic; heterocyclyl, which may be monocyclic or fused or non- fused polycyclic; monocyclic or fused or non-fused polycyclic aryl or heteroaryl; aryloxy; aralkyloxy; heterocyclyloxy; or heterocyclyl alkoxy. 
pri čemu određenje "supstituiran" označava supstituciju bilo kojim od supstituenata navedenim u naknadnim patentnim zahtjevima ili s halogenom; alkilom; hidroksilom; alkoksi; alkoksialkilom; amino; alkilaminom; karboksi; nitro; cijano; tiolom; tioeterom; iminom; imidom; amidinom; gvnidinom; enaminom; aminokarbonilom; acilaminom; fosfonatom; fosfinom; tiokarbonilom; sulfonilom; sulfonom; sulfonamidom; ketonom; aldehidom; esterom; ureom; uretanom; oksimom; hidroksil aminom; alkoksiaminom; aralkoksiaminom; N-oksidom; hidrazinom; hidrazidom; hidrazonom; azidom; izocijanatom; izotiocijanatom; cijanatom; tiocijanatom; kisikom (=O); B(OH)2, O(alkil)aminokarbonilom; cikloalkilom, koji može biti monociklički ili spojeni ili rastavljeni policiklički; heterociklilom, koji može biti monociklički ili spojeni ili rastavljeni policiklički; monociklički ili spojeni ili rastavljeni policiklički aril ili heteroaril; ariloksi; aralkiloksi; heterocikliloski; ili heterociklil alkoksi.
treating intolerance to said allergen in a subject wherein said probiotic and or prebiotic and allergen are to be administered sequentially or simultaneously to said subject; 
(a) liječenju intolerancije na spomenuti alergen kod subjekta pri čemu se navedeni probiotik i alergen hrane primenjuju sekvencijalno ili simultano kod spomenutog subjekta;
A process as claimed in Claim 1, wherein: the process is performed in the presence of formamidine, formamidine acetate, formamidine hydrohalide, formamidinesulfinic acid, or a mixture of ammonium chloride and formic acid; and/or 
(a) postupak se izvodi u prisutnosti formamidina, formamidin acetata, formamidin halogenvodika, formamidinsulfinske kiseline, ili smjese amonij klorida i mravlje kiseline; i/ili (b) I? predstavlja halo skupinu, sulfonatnu skupinu, ili oksi-acil skupinu.
The solid dosage forms (e,g.; tablets, capsules etc.) can be coated or un-coated, but typically have a coating, for example a protective film coating (e.g, a wax or varnish) or a release controlling coating. 
Kruti dozirni oblici (na primjer tablete, kapsule 1 slično) mogu biti prevučeno ili ne, ali obično imaju prevlaku, na primjer zaštitnu film prevlaku (na primjer vosak ili lak) ili imaju prevlaku za kontrolu oslobađanja.
A process according to claim 2, wherein the base is selected from the group consisting of NaOH, KOH and potassium tert-butylate. 
Postupak prema zahtjevu 2 ili 3, naznačen time, da je lužina odabrana iz skupine koju čine NaOH, KOH i kalijev tert-butilat.
an antioxidant, wherein the antioxidant and the carbohydrate are present in amounts sufficient to maintain the stability of the protein and wherein the pH of the composition is less than 7.0; 
Farmaceutska kompozicija prema zahtjevu 1, pri čemu je ugljikohidrat prisutan u količini koja je dovoljna za povećanje stabilnosti proteina.